Nucleoside reverse transcriptase inhibitors

MHRA Drug safety Update July 2009: Abacavir-containing medicines should be used in line with current treatment guidelines and with caution in patients with high cardiovascular risk factors. Action should be taken to minimise all modifiable risk factors (e.g. smoking, high blood pressure, hyperlipidaemia, and diabetes).

Tenofovir disoproxil

• Tablets 245mg
• Granules 33mg/g

Notes

1. NICE TA173: Tenofovir disoproxil (Viread), within its marketing authorisation, is recommended as an option for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated (July 2009)
   1. This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.

Non-nucleoside reverse transcriptase inhibitors

Doravirine

• Tablets 100mg

Notes

1. For use in line with the NHS England Clinical Commissioning Policy (November 2019)

Rilpivirine

• Edurant tablets 25mg
• Rekambys prolonged-release suspension for injection vials 900mg/3ml

Notes

1. NICE TA757: Cabotegravir (Vocabria) with rilpivirine (Rekambys) is recommended, within its marketing authorisation, as an option for treating HIV 1 infection in adults (January 2022):
   1. with virological suppression (HIV 1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen and
   2. without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors
   3. It is recommended only if the company provides it according to the commercial arrangement

Other antiretrovirals

Cabotegravir

• Tablets 30mg
• Prolonged-release suspension for injection vials 600mg/3ml

Notes

1. NICE TA757: Cabotegravir (Vocabria) with rilpivirine (Rekambys) is recommended, within its marketing authorisation, as an option for treating HIV 1 infection in adults (January 2022):
   1. with virological suppression (HIV 1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen and
   2. without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors
   3. It is recommended only if the company provides it according to the commercial arrangement